Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas ABSTRACT Purpose: To investigate the feasibility of combining concomitant boost-accelerated radiation regimen (ACB) with full-dose monochemotherapy using cisplatin and to assess its local response and acute toxicity patterns in patients with advanced loco-regional head and neck squamous cell carcinoma (HNSCC). th ) HNSCC of the oropharynx, hypopharynx and larynx who met the eligibility criteria was undertaken. Twenty-four of these patients (median age -53 years) were analyzable. The radiation dose was 72 Gy in 42 fractions over 6 weeks, delivered in one daily fraction of 1.8 Gy during the first 3.5 weeks and two fractions per day, 1.8 Gy and 1.5 Gy boost-separated by >6 h interval, during the last 2.5 weeks. cisplatin, 100 mg/m 2 , was given in intravenous (i.v.) infusion on day 1 and day 22. Tumor and clinical status were assessed and acute toxicities were graded.
INTRODUCTION
when the radiation dose per fraction is reduced. Accelerated fractionation regimens in radiation Improving the outcome for patients with locally therapy emerged through the recognition that advanced head and neck squamous cell carcinoma tumor clonogen proliferation occurring during (HNSCC) by rational modifications of radiation radiotherapy has a detrimental effect on fractionation regimens or combinations of outcome. [2, 3] Results of large randomized trials radiation with chemotherapy has been the subject addressing the optimization of radiation of intense clinical investigations for more than fractionation collectively show that a number of three decades. The two prototypes of biologically biologically sound altered fractionation schedules sound altered radiation fractionation regimens are improve the loco-regional (LR) control rate in the hyperfractionation and accelerated fractionation. [1] order of 10 to 15%, but they have only a modest Hyperfractionated radiotherapy is based on impact on overall survival. [1, 4] Although several preferential sparing of late-responding tissues altered fractionation regimens consistently induce more severe acute mucositis than the standard 7-week radiotherapy, the general consensus is that late toxicities are not appreciably increased.
Results of scores of clinical trials testing combined modality therapy have been published. Meta-analysis of the data revealed that, in aggregate, cytotoxic agents administered before (induction or neoadjuvant chemotherapy) or after (adjuvant chemotherapy) surgery or radiation do not improve the therapeutic outcome appreciably over loco-regional treatment alone. In contrast, chemotherapy administered concurrently with radiation has improved the 2-and 5-year overall survival rates by 8% [5] but unfortunately, at the expense of increased toxicity. [6] The data of five recent trials addressing standard radiation fractionation with or without cisplatin have been reported. [7] [8] [9] [10] [11] All five trials showed superior outcome in favor of the combined regimen in terms of loco-regional control or organ preservation and three trials also showed improvement in survival. [7, 8, 11] Six other trials also show varying degrees of benefits of combining various radiation schedules concurrently with other chemotherapy regimens. [12] [13] [14] [15] [16] [17] Despite these consistent data, the best regimen to be recommended for the treatment of patients with advanced HNSCC remains unclear.
A phase III trial of the Radiation Therapy Oncology Group (RTOG 90-03), which enrolled 1,113 patients, revealed that both hyperfractionated regimen and accelerated fractionation by concomitant boost regimen (ACB) yielded significantly better loco-regional control than standard fractionation in patients with advanced HNSCC. [18] Based on these findings, a pilot study was planned to test the combination of ACB with cisplatin in patients with advanced loco-regional HNSCC. Single-agent Cisplatin (CDDP) was chosen because it was found to improve outcome when combined with conventionally fractionated radiotherapy in five phase III cooperative group trials. [7] [8] [9] [10] [11] 
MATERIALS AND METHODS

Study objectives and patient eligibility
Patients with previously untreated locally advanced (stage III IVB) HNSCC of the oropharynx, hypopharynx or larynx who had a ECOG performance status of 0 to 1, met the blood count and liver function test criteria and opted to receive nonsurgical primary therapy were enrolled. Patients younger than 18 years or with a prior (within 5 years) or synchronous malignancy other than nonmelanoma skin cancer were excluded. A medical history and physical examination, CBC, chest X-ray, computed tomography imaging of the head and neck, diagram of the primary tumor and the neck nodes and dental evaluation were required. The disease was staged according to the 2002 classification of the American Joint Committee on Cancer Staging. The ethics committee of the institute cleared the study and written informed consent was obtained from all the patients.
Treatment
Radiation therapy was delivered in 180 cGy per fraction, 5 fractions a week, to 54 Gy in 30 fractions over 6 weeks to the initial target volume encompassing gross tumor and clinically involved nodes along with regions of potential contiguous and lymphatic spread. At 32.4 Gy in 18 fractions (i.e., latter part of week 4), a second daily dose of 150 cGy per fraction (with at least a 6-hour interval) was administered to the boost volume covering gross tumor and the involved nodes for a total of 18 Gy in 12 treatment days. The primary tumor and clinically and radiologically involved nodes received 72 Gy in 42 fractions over 6weeks and uninvolved nodes received 54 Gy in 6weeks. A combination of lateral opposed portals was used to treat the primary tumor and lymph nodes in the neck. Both fields were treated on each treatment day using a Telecobalt teletherapy machine.
Cisplatin was administered in a dose of 100 mg/m 2 intravenously on days 1 and 22 with ondansetron or granisetron premedication and vigorous hydration and diuresis. Guidelines for dose modification because of cytopenia, neurotoxicity or nephrotoxicity were specified in the protocol [ Table 1 ]. Neck dissection was allowed for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (i.e., N2 and N3) when complete nodal response was not achieved. Neck dissection was required for patients with a palpable or suspicious radiographic abnormality persisting 6 weeks beyond completion of radiation and chemotherapy. [19] Follow-up and data analysis Patients were treated as inpatients and underwent weekly examination during treatment. As the toxicities were estimated to be higher than the conventional treatment protocols, our institute requirements necessitated treating all our patients as inpatients after seeking their consent. All patients consented to undergo inpatient care. We however feel that inpatient treatment, though advisable, is not mandatory for this treatment 1. Neutropenia -If on the day of scheduled treatment with cisplatin, the absolute neutrophil count (ANC) was < 1000, treatment was held until ANC > 1000 then the patient was treated at 100% dose. 2. Thrombocytopenia -If on the day of scheduled treatment with cisplatin the platelet count was < 75,000, treatment was held until platelets were ≥ 75,000 and then the patient was treat at 100% dose. 3. Neurotoxicity -If signs of paralysis, moderate myopathy, moderate weakness, seizure or peripheral neuropathy occurred, cisplatin was discontinued. 4. Renal Toxicity: Cisplatin was administered on the scheduled day of treatment using the following guidelines.
Creatinine clearance cisplatin dose > 50 ml/min. 100 mg/m protocol. Following the treatment, first follow-up for evaluation occurred around 6 weeks after completion. Subsequently, patients are being assessed every 3 months for the first 2 years and thereafter it is proposed to follow up every 6 months in years 3 to 5 and annually thereon. Tumor response was assessed as per the RECIST criteria. [20] In addition to tumor and clinical status, acute toxicity was graded. Systemic and acute radiation effects were scored using the National Cancer Institute Common Toxicity Criteria version 2.0.
The primary end point of the study was the loco-regional response at 6 weeks. An additional end point was the acute toxicity rate. Apart from describing the distribution of different variables, Chi-square test, cross-tabulation and percentage analysis were applied to the data available to determine the significance and relationship between the variables.
RESULTS
Study population and compliance to treatment
Between July 2004 and August 2005, 27 patients met the eligibility criteria of the protocol and were recruited. Three patients were excluded from the study because of the following respective reasons: one patient opted out of the protocol therapy early on, one did not receive protocol therapy and the third one had delinquent data. Tables 2 and 3 list pretreatment patient and tumor characteristics. Some significant observations noted on comparison of patients with respect to different primary sites were that dysphagia and odynophagia were common presenting symptoms in patients with oropharynx; voice change was the common presenting symptom among patients with laryngeal cancer; and in hypopharyngeal cancers, the common presenting symptoms were swelling, pain and dysphagia (P < 0.01). Nasogastric tube feeding was increasingly required prior to treatment for cancers of the hypopharynx and oropharynx (P < 0.05). Computed tomography helped upstage the disease in 16 patients (67%).
The fractionation regimen was according to protocol specification in all patients (100%). The duration of radiation therapy was ≤46 days in 22 patients (92%) and was 47-51 days in 2 patients (8%). All the patients received both cycles of cisplatin. Dose modification for the second cycle was required in 2 patients because of toxicity. All patients received therapy as per protocol or acceptable variations for both radiation and chemotherapy.
Tumor response
Response to therapy was recorded in 23 patients (95.8%). This included a complete response in 19 patients (79.1%) and partial response in 4 patients (16.7%). One patient (4.2%) had progressive disease; there was progression of disease at the primary tumor site, while there was partial response at the nodal site. Of the 4 patients with residual disease (partial response), 2 patients (8.3%) had residual disease at the primary site, one patient (4.2%) had residual disease of the nodes and 1 patient (4.2%) had residual disease at both the primary and nodal site. Table 4 shows the response distribution and [ Figure 1 ] illustrates the stage-wise response.
A significant observation was the association between the grade of squamous cell carcinoma and complete response; 100% of grade I, 85.7% of grade II and 33.3% of grade III carcinomas
% Response
Vivek RS, et al.: Concurrent chemo-irradiation showed complete response (P < 0.01). With respect to site, 100% of laryngeal cancers, 88.9% of hypopharyngeal cancers and 66.7% of oropharyngeal cancers showed complete response (P = NS). One hundred percent of T2 tumors, 92.3% of T3 tumors and 71.4% of T4a tumors showed complete response (P = NS). With respect to nodal stage, 100% complete response was observed among patients with N1 and N2b lesions, while N2c and N3 lesions showed 84.6 and 50% complete response respectively (P = NS).
Acute toxicity
One patient died of sepsis and pneumonia attributable to treatment-induced neutropenia (grade 5 toxicity); the lethal event occurred during the acute period and within 5 weeks of completing the treatment. The patient had shown complete response to the treatment. Three patients (12.5%) experienced acute grade 4 side effects and 17 patients (70.8%) had acute grade 3 side effects -the predominant adverse event being mucositis. The most common acute grade 4 side effects in decreasing frequency were mucositis and hematological toxicity. Grade 3 side effects commonly occurred in relation to mucositis, skin reactions, hematological toxicity, nausea/vomiting, dysphagia and renal toxicity. Table 5 lists the type and frequency of adverse events.
There was no significant relationship between the toxicities observed and the site and stage of disease and the type of response. Of the 12 patients who did not receive any feeding procedure prior to the start of treatment, 6 (50%) received some form of feeding procedure or parenteral nutrition during and after treatment. Only one patient (4.2%) continues to have a feeding tube on last follow-up.
DISCUSSION
With respect to the findings that a number of modified radiation fractionation and concurrent chemoradiation regimens are more effective than conventionally fractionated radiation therapy in the treatment of advanced HNSCC, there is an enthusiasm to test the combination of altered fractionation regimens along with chemotherapy. In a retrospective study, for example, Wolden et al [21] compared the data of 50 patients with nasopharyngeal carcinoma who had received concomitant boost radiation with two cycles of concurrent cisplatin (plus cisplatin-based adjuvant chemotherapy in most cases) with the data of an earlier cohort of 51 patients matched for prognostic factors who were treated with radiotherapy alone. They showed that the loco-regional control, progression-free survival and overall survival rates were better in the combined treatment group. Of note is the fact that the regimen used was comparable to treatment regimens used by many cooperative groups and this study.
In comparison with chemoradiation treatment strategies attempted in this institution, this treatment protocol compares favorably. A concurrent chemoradiation study conducted in this institution with conventional radiation and concurrent Hematologic  6  10  7  1  -Infection, febrile neutropenia  5  3  1  -1  Pulmonary  3  -1  --Renal  10  2  3  --Dysphagia  8  9  7  --Mucositis  -4  17  3  -Dehydration  4  17  3  --Nausea/vomiting  13  3  8  --Auditory  1  1  ---Skin  2  12  10  --Constitutional symptoms  -23  1  --Hepatic  1  1  ---Pain  10  11  3 --chemotherapy using cisplatin (3 cycles) had yielded a complete response rate of 69% and acute grade 3 toxicity rates of 61.6%. Another study that evaluated hyperfractionated radiation therapy and concurrent cisplatin-5FU chemotherapy (2 cycles, week 1 and 5) recorded a complete response of 73.1% and acute grade 3 toxicity of 62%. Thus, with a marginally increased but acceptable level of toxicity, the response rate and feasibility achieved in this study were an improvement by about 6-10%. A study that evaluated altered fractionation radiation therapy alone delivered by accelerated concomitant boost regimen for loco-regionally advanced HNSCC at this department recorded a complete response rate of 60% and acute grade 3 toxicity of 46.2%.
The results of six phase III trials testing the efficacy of such combinations of altered fractionation regimens with concurrent chemotherapy against radiation alone have been reported. The radiation regimens used were accelerated fractionation in three trials, [17, 22] hyperfractionation in one study [16] and split-course altered fractionation in two trials. [12, 13, 23] The results of these trials are listed in Table 6 . Collectively, most trials show that combinations of modified fractionation regimens with chemotherapy achieved better local control and, in several trials, improved survival compared with standard or altered fractionation alone. However, the value of altered fractionation in the concurrent chemoradiation setting (i.e., the potential benefit of combining altered fractionations instead of standard fractionation with chemotherapy) has not been tested. Building on the results of RTOG 90-03, which show loco-regional tumor control benefit by concomitant boost regimen, [18] RTOG 99-14 undertook a phase II trial to determine the feasibility of delivering two cycles of Cisplatin (100 mg/m 2 ) on days 1 and 22 of ACB in a cooperative group setting. This study showed an estimated 2-year overall survival and disease-free survival of 71.6 and 53.3% respectively. The complete response rate in this study was 83% and acute grade 4 and grade 3 toxicity rates were 25 and 64% respectively. [24] Our study was based on the RTOG 99-14 trial, but in the setting of a developing country and a high-load Telecobalt treatment facility. All the patients completed the treatment, both radiation and chemotherapy, as specified or with very minor variations. The acute toxicity of the treatment was severe, but this was expected. The toxic death rate was 3.7% (1 patient) and is in the range of 2-5% observed in other trials testing cisplatin-based chemotherapy with radiation therapy. [8, 9] Comparing the acute toxicity of this study with trials conducted by several institutions is difficult because of the inconsistency in recording and reporting of toxicities, as clearly pointed out by Trotti and Bentzen. [25] These authors noted that four different recognized grading systems and two descriptive efforts had been used in reporting the results of nine frequently cited trials addressing the combination of radiation and chemotherapy in HNSCC published within the last decade. Comparison of the results of this study with these [17] Stg III-IV (70 mg/m 2 /day) and 5-FU (P=0.11) 2 yr LC: 51% grade 3-4 mucositis (68% (600 mg/m 2 /day) for 5d x 2 V 45% (P=0.14) V 52%, P=0.01) vomiting 69.9 Gy-5. other trials revealed similar incidences of grade 3 and grade 4 adverse effects. [26] CONCLUSION This data shows that it is feasible to combine ACB and fulldose mono-chemotherapy using cisplatin with manageable, although substantial, toxicity. The compliance to therapy was high and the loco-regional response achieved compared favorably with ACB alone or other concurrent chemoradiation regimens using standard or altered fractionation regimens tested by the Institute. It also compares well with the available literature. An extended phase II trial and a new phase III trial comparing ACB plus cisplatin against standard radiation plus cisplatin are being planned at the institute to determine whether the use of ACB in the concurrent chemoradiation setting further improves outcome.
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